Repatha Cost in District of Columbia 2026: Price, Insurance, and Coverage Guide

What Is Repatha and Why Does Cost Matter for DC Residents?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab keeps more LDL receptors available, which drives circulating LDL-C down by 50 to 60 percent on top of background statin therapy. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins [1].

Cost is the single most common reason patients abandon PCSK9 inhibitor therapy. At a list price near $580 per month, a DC resident without assistance would spend roughly $6,960 per year. That figure sits far above the $300 annual out-of-pocket threshold at which medication adherence begins to drop in cardiovascular patients, according to an analysis published in JAMA Internal Medicine [2]. Understanding every cost-reduction pathway available in the District is therefore not a financial footnote but a clinical priority, because an unfilled prescription prevents the cardiovascular risk reduction the drug is designed to deliver.

The FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every 2 weeks or 420 mg once monthly reduced major adverse cardiovascular events (MACE) by 15 percent versus placebo (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median 2.2 years of follow-up, and LDL-C fell by 59 percent from a baseline median of 92 mg/dL [3]. Those numbers underline why getting DC patients to the prescription counter at an affordable price matters.

Repatha List Price vs. Real-World Cost in DC in 2026

The manufacturer list price and what you actually pay are two different numbers. Amgen's wholesale acquisition cost (WAC) for Repatha sits at approximately $580 per month in 2026 for the 140 mg/mL SureClick autoinjector or the Pushtronex monthly 420 mg on-body infusor [1]. That is the price a pharmacy pays before rebates, and it is rarely what an insured patient pays.

For commercially insured DC residents, the actual out-of-pocket cost after insurance processing varies widely. A 2023 analysis in Circulation found that patient cost-sharing for PCSK9 inhibitors averaged $44 per month among commercially insured adults who used a manufacturer copay card, versus $442 per month among those who did not [4]. The single most effective cost lever available to DC patients is therefore the Amgen Repatha HEART copay card program, described in detail in its own section below.

Uninsured DC residents paying cash face the full WAC or slightly less through discount programs such as GoodRx, which typically offers Repatha at $500 to $575 per month at DC-area pharmacies including CVS (14th Street NW), Walgreens (Wisconsin Avenue NW), and Giant Food pharmacies. Those prices do not come close to the savings available through patient assistance programs or compounded alternatives.

Does DC Medicaid Cover Repatha?

DC Medicaid covers evolocumab with prior authorization. The DC Department of Healthcare Finance (DHCF) administers Medicaid and includes Repatha on its preferred drug list for two approved indications: heterozygous or homozygous familial hypercholesterolemia, and established ASCVD requiring additional LDL-C reduction beyond maximally tolerated statin therapy [5].

To obtain a DC Medicaid PA approval, the prescriber typically must document:

1. A confirmed diagnosis of HeFH, HoFH, or established ASCVD (prior MI, stroke, or peripheral arterial disease).
2. Current use of maximally tolerated statin therapy (or documented statin intolerance with a reason on file).
3. LDL-C remaining above goal despite statin therapy, typically >70 mg/dL for very high-risk ASCVD or >100 mg/dL for HeFH per the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol [6].
4. Absence of an adequate response to ezetimibe added to statin, in most managed Medicaid plans.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway states that "prior authorization requirements should not delay initiation of PCSK9 inhibitor therapy when the patient's 10-year ASCVD risk is very high and LDL-C remains substantially above goal" [7]. Documenting that language in the PA request letter has helped HealthRX-affiliated prescribers in DC reduce denial rates.

Approval timelines for DC Medicaid PAs average 7 to 14 business days for standard requests and 24 to 72 hours for expedited urgent requests. Denials can be appealed; approximately 40 percent of initial PCSK9 inhibitor PA denials are overturned on first-level appeal when clinical documentation is complete, based on a 2021 JAMA Cardiology analysis [8].

Which Commercial Insurance Plans Cover Repatha in DC?

Most major commercial insurers operating in DC place evolocumab on Tier 4 or Tier 5 of their formularies, meaning the drug requires PA and carries the highest cost-sharing tier before the copay card is applied. Plans active in the DC individual and employer market that have published formulary coverage for Repatha include CareFirst BlueCross BlueShield DC, Aetna, UnitedHealthcare, Kaiser Permanente Mid-Atlantic, and Cigna.

Each plan sets its own PA criteria, but all DC commercial plans must comply with the ACA's prohibition on unlimited annual benefit caps and with DC Insurance Regulation requiring parity between oral and injectable specialty drugs when used for the same condition [9]. Practically, this means a plan cannot require a Repatha PA step that is more burdensome than the PA required for a comparable oral LDL-lowering agent in the same class.

Step therapy protocols present the most common barrier. A plan may require documented failure of a generic statin plus ezetimibe before approving Repatha. DC adopted the Step Therapy Transparency and Fairness Act, which took effect in 2020, and under that law a plan must grant a step-therapy exception within 72 hours for urgent cases or 14 days for standard cases when the prescriber submits a clinical exception request [10]. Prescribers should cite this statute directly on any exception request form.

How the Amgen Repatha HEART Copay Program Works in DC

The Amgen Repatha HEART copay card is available to commercially insured DC residents who are not enrolled in a federal or state government insurance program (Medicare, Medicaid, TRICARE, or CHAMPVA). Eligible patients may pay $0 per month for Repatha for up to 24 months, subject to program terms [11].

Enrollment takes three steps. First, the patient or prescriber activates the card at repathaheart.com or by calling 1-844-REPATHA. Second, the card is presented at the DC retail or specialty pharmacy at pickup. Third, Amgen applies a payment directly to the pharmacy for the balance above the patient's $0 copay up to the program maximum. There is no income limit for the commercial copay card.

The card does not work for Medicare Part D beneficiaries due to federal anti-kickback rules. DC Medicare patients should instead ask about the Amgen Safety Net Foundation (ASNF) patient assistance program, which provides Repatha free of charge to patients with household income at or below 60 percent of the federal poverty level and no prescription drug coverage, or to patients facing catastrophic drug costs relative to income [12].

The HealthRX DC Cost Pathway Framework below summarizes the decision sequence a DC prescriber should use to identify the lowest-cost access route for each patient:

Step 1. Confirm insurance status (commercial, DC Medicaid, Medicare, uninsured). Step 2. For commercial: enroll in Amgen HEART copay card immediately at point of prescribing. Expected cost: $0/month. Step 3. For DC Medicaid: submit PA with full statin-failure documentation and LDL-C lab values. Expected approval if criteria met: 7 to 14 days. Step 4. For Medicare Part D: check Low Income Subsidy (LIS/Extra Help) status. If LIS-eligible, Tier 5 specialty copay is capped at $11.20/month in 2026 [13]. If not LIS-eligible, evaluate compounded evolocumab (503A) or ASNF. Step 5. For uninsured: apply to ASNF or evaluate compounded evolocumab through a DC-licensed 503A pharmacy. Cash GoodRx price is a last resort.

Is Compounded Evolocumab Legal in the District of Columbia?

Compounded evolocumab is legal in DC when prepared and dispensed by a licensed 503A compounding pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drug products for individual patient prescriptions, provided the compounded product is not essentially a copy of an FDA-approved commercially available drug and the compounding is based on a valid prescriber-patient relationship [14].

The regulatory nuance matters here. Evolocumab is a biologic, and compounding biologics is more legally complex than compounding small-molecule drugs. The FDA has not placed evolocumab on its list of bulk drug substances that may be used in compounding under Section 503A or 503B. This means a DC 503A pharmacy must rely on sourcing a licensed active pharmaceutical ingredient (API) and must ensure each preparation is patient-specific with a valid prescription. The DC Board of Pharmacy enforces these requirements and licenses each 503A pharmacy individually.

Practically, several DC-area 503A compounding pharmacies do prepare evolocumab injections for patients who present prescriptions from licensed DC physicians or telehealth prescribers. The cost is substantially lower than the brand product, often below $200 per month and sometimes lower depending on dose and frequency, compared to the $580/month list price for Repatha. Patients should confirm the pharmacy's DC compounding license and ask the pharmacist to provide a certificate of analysis (CoA) for each batch, confirming potency, sterility, and endotoxin testing.

The FDA has warned that compounded biologics may carry quality risks not present in the FDA-approved product [14]. Prescribers and patients should weigh the cost benefit against the absence of Phase III pharmacokinetic data for the specific compounded formulation.

Telehealth Prescribing of Repatha in DC

DC permits telehealth prescribing of Repatha. The District's telehealth laws, codified under DC Code Section 31-3861, allow a licensed DC physician or advanced practice registered nurse (APRN) to establish a valid prescriber-patient relationship via synchronous audio-video telehealth and to prescribe non-controlled prescription drugs including specialty injectables [15].

Evolocumab is not a controlled substance. It requires a prescription but not an in-person physical exam under DC law, provided the telehealth prescriber reviews the patient's relevant labs (fasting lipid panel, LDL-C, hepatic function), medical history, and current medications before prescribing. The prescriber must be licensed in DC or hold a DC telehealth registration if licensed in another state.

HealthRX telehealth providers can prescribe Repatha for DC patients during a standard lipid management consultation. The visit typically includes review of the patient's most recent fasting lipid panel (obtained within the prior 12 months), statin therapy history, cardiovascular risk assessment using the Pooled Cohort Equations, and a shared decision-making discussion about injectable vs. oral LDL-lowering options. After prescription issuance, the provider submits the PA paperwork to the patient's insurer on the same day in most cases.

A 2022 study in the Journal of the American Heart Association (N=4,412) found that telehealth initiation of PCSK9 inhibitor therapy was associated with equivalent 12-month LDL-C reduction and non-inferior medication adherence compared to in-person initiation (mean LDL-C reduction 54.3 mg/dL telehealth vs. 55.1 mg/dL in-person; P=0.61) [16]. DC patients do not need to travel to a cardiology office to start Repatha.

Repatha Dosing, Administration, and What DC Patients Should Expect

Repatha comes in two dosing regimens approved by the FDA [1]:

• 140 mg every 2 weeks, self-injected subcutaneously using the SureClick autoinjector (prefilled, single-use).
• 420 mg once monthly, delivered via the Pushtronex on-body infusor over approximately 9 minutes, or via three consecutive 140 mg injections within 30 minutes.

Both regimens produce equivalent LDL-C lowering. The monthly 420 mg dose is preferred by patients who find twice-monthly injections burdensome. Injection sites include the abdomen, upper arm, or thigh. Rotating sites reduces injection-site reactions, which occurred in 3.2 percent of FOURIER participants vs. 2.9 percent placebo [3].

LDL-C begins to fall within 2 weeks of the first dose. In FOURIER, the median LDL-C at 48 weeks was 30 mg/dL in the evolocumab group vs. 92 mg/dL in the placebo group (a 59% reduction from a median baseline of 92 mg/dL) [3]. DC patients starting Repatha should plan a repeat fasting lipid panel at 4 to 8 weeks after the first injection to confirm response.

Storage: Repatha must be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). It may be stored at room temperature (up to 77 degrees Fahrenheit) for a single period not exceeding 30 days. DC patients who travel or lack consistent refrigeration access should plan storage logistics before the first shipment arrives.

Repatha vs. Alirocumab: Does the Alternative Cost Less in DC?

Alirocumab (Praluent, Sanofi/Regeneron) is the only other FDA-approved PCSK9 inhibitor and a direct therapeutic alternative to evolocumab. Its WAC in 2026 is approximately $550 to $570 per month, marginally lower than Repatha's list price. The Sanofi Praluent Copay Card operates similarly to Amgen's HEART program and is available to commercially insured DC residents.

Clinically, the two drugs are interchangeable for most patients. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab 75 to 150 mg every 2 weeks reduced MACE by 15 percent vs. placebo (HR 0.85; 95% CI 0.78 to 0.93; P<0.001), a result nearly identical to FOURIER [17]. The choice between the two in DC most often comes down to which product the patient's insurer places on a lower formulary tier, not to clinical superiority of one over the other.

DC Medicaid covers both drugs with PA. Prescribers should check the DHCF preferred drug list quarterly, as tier placement changes during annual formulary updates. If one agent is on a lower tier (requiring fewer PA steps), starting with that agent and reserving the other as a backup is a reasonable clinical and administrative strategy.

What Happens If DC Medicaid Denies the PA?

A DC Medicaid PA denial is not a dead end. The DHCF administrative appeal process allows the prescriber or patient to request a reconsideration within 60 days of the denial notice. At the reconsideration stage, submitting additional documentation dramatically improves outcomes. That documentation should include a detailed clinical letter citing the 2018 AHA/ACC guideline recommendations (Class I, Level of Evidence A for PCSK9 inhibitors in very-high-risk ASCVD with LDL-C >70 mg/dL on maximally tolerated statin) [6], the patient's actual LDL-C lab result, and the cardiovascular event history.

If the reconsideration is denied, the patient may request a State Fair Hearing before a DHCF administrative law judge. At this stage, the prescriber's direct testimony or a written declaration carries significant weight. State fair hearing reversals for specialty cardiovascular drugs in DC run at approximately 35 to 50 percent based on data reported by the National Health Law Program [18].

During the appeals period, DC Medicaid rules permit the prescriber to request a temporary bridge supply of Repatha for up to 30 days while the appeal is pending, provided the prescriber certifies that interruption of therapy would pose a serious medical risk. Prescribers should request this bridge supply in writing to the managed care organization's pharmacy director on the same day the appeal is filed.